产品名称(Product Name)

制造商(Sponsor)

适应症(Indication)

在研阶段(Development Phase)

abemaciclib
(CDK 4/6 inhibitor)

Lilly
Indianapolis, IN

non-small-cell lung cancer (NSCLC)
(see also breast, lymphoma)

Phase I
www.lilly.com

ABT-RTA-408

AbbVie
North Chicago, IL
Reata Pharmaceuticals
Irving, TX

metastatic NSCLC
(see also skin)

Phase I
www.abbvie.com
www.reatapharma.com

ADI-PEG 20
(PEG arginine deiminase)

Polaris Pharmaceuticals
San Diego, CA

small-cell lung cancer (SCLC)
(see also breast, leukemia, liver, lymphoma, skin)
--------------------------------
mesothelioma, NSCLC

Phase II
www.polarispharma.com
--------------------------------
Phase I
www.polarispharma.com

A­finitor?
everolimus

Novartis Pharmaceuticals
East Hanover, NJ

neuroendocrine lung tumors
(see also breast, lymphoma, stomach)

Phase III
www.novartis.com

aldoxorubicin
(delivery-enhanced doxorubicin)

CytRx
Los Angeles, CA

SCLC
(see also brain, sarcoma)

Phase II
www.cytrx.com

alectinib
(ALK inhibitor)

Chugai Pharma USA
Berkeley Heights, NJ
Roche
Basel, Swizterland

NSCLC
(Breakthrough Therapy)

Phase II
www.chugai-pharm.com
www.roche.com

alisertib
(auroura A kinase inhibitor)

Millennium Pharmaceuticals
Cambridge, MA

SCLC
(see also lymphoma, ovarian)

Phase II
www.millennium.com

antroquinonol

Golden Biotechnology
New Taipei City, Taiwan

NSCLC

Phase II
www.goldenbiotech.com.tw

AP26113
(ALK inhibitor)

ARIAD Pharmaceuticals
Cambridge, MA

NSCLC

Phase II
www.ariad.com

apatorsen
(Hsp27 inhibitor)

OncoGenex Pharmaceuticals
Bothell, WA

non-squamous NSCLC, squamous NSCLC
(see also bladder, pancreatic, prostate)

Phase II
www.oncogenex.com

ASP8273

Astellas Pharma US
Northbrook, IL

NSCLC

Phase I/II
www.astellas.com

AT13387
(HSP90 inhibitor)

Astex Pharmaceuticals
Dublin, CA

NSCLC
(see also skin)

Phase II
www.astx.com

Avastin?
bevacizumab

Genentech
South San Francisco, CA

NSCLC (adjuvant)
(see also brain, ovarian, other)

Phase III
www.gene.com

AZD9291
(EGFR tyrosine kinase inhibitor)

AstraZeneca
Wilmington, DE

advanced T790M mutation-positive NSCLC
(Breakthrough Therapy)

Phase II/III
www.astrazeneca.com

bavituximab

Peregrine Pharmaceuticals
Tustin, CA

NSCLC (2nd-line)
(see also breast, liver, skin, other)
--------------------------------
NSCLC (1st-line)

Phase III
www.peregrineinc.com
--------------------------------
Phase I
www.peregrineinc.com

BBI608
(cancer stemness kinase inhibitor)

Boston Biomedical
Cambridge, MA

NSCLC
(see also breast, colorectal, ovarian, skin, stomach)

Phase I/II
www.bostonbiomedical.com

belinostat

Spectrum Pharmaceuticals
Henderson, NV

NSCLC

Phase I/II
www.sppirx.com

bevacizumab biosimilar

Actavis
Parsippany, NJ
Amgen
Thousand Oaks, CA

NSCLC

Phase III
www.actavis.com
www.amgen.com

BIND-014
(PSMA-targeted docetaxel)

BIND Therapeutics
Cambridge, MA

NSCLC
(see also prostate)

Phase II
www.bindtherapeutics.com

CRS-207
(cancer immunotherapy)

Aduro BioTech
Berkeley, CA

mesothelioma (combination therapy)
(see also pancreatic)

Phase I
ww.adurobiotech.com

custirsen (OGX-111)
(antisense oligonucleotide)

OncoGenex Pharmaceuticals
Bothell, WA
Teva Pharmaceutical
Frazier, PA

NSCLC (Fast Track)
(see also prostate)

Phase III
www.oncogenex.com
www.tevapharm.com

Cynviloq?
paclitaxel polymeric micelle for injection

Sorrento Therapeutics
San Diego, CA

NSCLC
(see also bladder, breast, ovarian, pancreatic)

Phase III
www.sorrentotherapeutics.com

Cyramza?
ramucirumab

Lilly
Indianapolis, IN

NSCLC (combination therapy)
(see also bladder, breast, colorectal, liver, ovarian, solid tumors, stomach)

Phase III
www.lilly.com

CYT-6091
(nanomedicine)

CytImmune Sciences
Rockville, MD

NSCLC (2nd-line)

Phase II
www.cytimmune.com

dacomitinib
(pan-HER inhibitor)

Pfizer
New York, NY

EGFR-mutant NSCLC (1st-line)
(see also solid tumors)

Phase III
www.p­fizer.com

DKN-01
(DKK1 protein inhibitor)

HealthCare Pharmaceuticals
Cambridge, MA

NSCLC
(see also myeloma, other)

Phase I
www.healthcarepharmaceuticals.com

DPV-001
(toll-like receptor agonist)

UbiVac
Portland, OR

NSCLC

Phase II
www.ubivac.com

E7080
(multi-targeted kinase inhibitor)

Eisai
Woodcli? Lake, NJ

NSCLC (3rd-line monotherapy), NSCLC (RET translocations)
(see also brain, liver, skin, other)

Phase II
www.eisai.com

EGF816
(EGFR TK inhibitor)

Novartis Pharmaceuticals
East Hanover, NJ

NSCLC

Phase I/II
www.novartis.com

­ficlatuzumab
(HGF/c-MET inhibitor)

AVEO Oncology
Cambridge, MA

NSCLC

Phase II
www.aveooncology.com

foretinib
(c-MET kinase inhibitor)

GlaxoSmithKline
Research Triangle Park, NC

NSCLC

Phase II
www.gsk.com

ganetespib
(Hsp90 inhibitor)

Synta Pharmaceuticals
Lexington, MA

NSCLC
(Fast Track)
(see also breast, leukemia, ovarian)

Phase III
www.syntapharma.com

GI-4000
(natural killer cell stimulant)

GlobeImmune
Louisville, CO

NSCLC
(see also pancreatic)

Phase II
www.globeimmune.com

GL-ONC1
(oncolytic virus immunomodulator)

Genelux
San Diego, CA

lung, malignant mesothelioma
(see also head/neck, solid tumors, other)

Phase I
www.genelux.com

GSK2879552
(LSD1/CoREST inhibitor)

GlaxoSmithKline
Research Triangle Park, NC

relapsed/refractory SCLC

Phase I
www.gsk.com

Halaven?
eribulin

Eisai
Woodcli? Lake, NJ

NSCLC
(see also breast, sarcoma)

Phase III
www.eisai.com

Imprime PGG?
intravenous immunostimulant

Biothera
Eagan, MN

metastatic NSCLC (1st-line)
(see also colorectal, leukemia, lymphoma, pancreatic)

Phase II
www.biothera.com

INCB24360
(IDO1 inhibitor)

Incyte
Wilmington, DE

NSCLC
(see also ovarian, skin, other)

Phase I/II
www.incyte.com

INCB39110
(JAK1 inhibitor)

Incyte
Wilmington, DE

NSCLC
(see also solid tumors)

Phase I/II
www.incyte.com

ISIS-EIF4ERX
(antisense oligonucleotide)

Isis Pharmaceuticals
Carlsbad, CA

NSCLC
(see also prostate)

Phase II
www.isispharm.com

Jaka­fi?
ruxolitinib

Incyte
Wilmington, DE

NSCLC
(see also breast, colorectal, pancreatic, other)

Phase I
www.incyte.com

KD019
(TKI inhibitor)

Kadmon Pharmaceuticals
Warrendale, PA

NSCLC
(see also breast)
--------------------------------
Src-positive NSCLC

Phase II
www.kadmon.com
--------------------------------
Phase I
www.kadmon.com

KD032
(Ras antagonist)

Kadmon Pharmaceuticals
Warrendale, PA

NSCLC
(see also colorectal, pancreatic)

Phase II
www.kadmon.com

Keytruda?
pembrolizumab

Merck
Whitehouse Station, NJ

NSCLC
(see also bladder, breast, head/neck, hematological, kidney, myeloma, stomach)

Phase III
www.merck.com

Kyprolis?
car­ lzomab

Onyx Pharmaceuticals
South San Francisco, CA

SCLC
(see also myeloma)

Phase II
www.onyx.com

lifastuzumab vedotin
(anti-NaPi2b antibody drug conjugate)
(RG7599)

Genentech
South San Francisco, CA

NSCLC
(see also ovarian)

Phase I
www.gene.com

lucitanib
(FGFR/VEGFR/PDGFR inhibitor)

Clovis Oncology
Boulder, CO

squamous NSCLC
(see also breast)

Phase II
www.clovisoncology.com

lung cancer DNA vaccine
(IC 1001)

Immune Cell Therapy
Chicago, IL

NSCLC

Phase I
www.immcellther.com

LY2510924
(CXCR4 peptide antagonist)

Lilly
Indianapolis, IN

SCLC
(see also kidney)

Phase II
www.lilly.com

LY2875358
(c-Met mAb)

Lilly
Indianapolis, IN

NSCLC
(see also stomach)

Phase II
www.lilly.com

LY2940680
(hedgehog/SMO antagonist)

Lilly
Indianapolis, IN

SCLC

Phase I/II
www.lilly.com

MAGE-A3 immunotherapeutic
(recombinant antigen-speci­ c cancer immunotherapeutic)

GlaxoSmithKline
Research Triangle Park, NC

NSCLC

Phase III
www.gsk.com

ME-344
(mitochondrial inhibitor)

MEI Pharma
San Diego, CA

SCLC
(see also ovarian)

Phase I
www.meipharma.com

MEDI4736
(anti-PD-L1 mAb)

MedImmune
Gaithersburg, MD

stage III NSCLC, NSCLC (3rd-line)

Phase III
www.medimmune.com

MEDI4736 + Iressa? ge­fitinib
(anti-PD-L1 mAb/EGFR inhibitor)

MedImmune
Gaithersburg, MD

NSCLC

Phase I
www.medimmune.com

MGCD265
(MET/Axl/VEGFR kinase inhibitor)

Mirati Therapeutics
San Diego, CA

NSCLC
(see also head/neck)

Phase I
www.mirati.com

MM-121
(ErbB-3 receptor antagonist)

Merrimack Pharmaceuticals
Cambridge, MA

NSCLC
(see also breast, ovarian)

Phase II
www.merrimackpharma.com

MORAb-003
(IgG1 mAb)

Eisai
Woodcli? Lake, NJ
Morphotek
Exton, PA

NSCLC
(see also ovarian)

Phase II
www.eisai.com

MORAb-009
(megakaryocyte potentiating factor inhibitor)
ORPHAN DRUG

Eisai
Woodcli? Lake, NJ
Morphotek
Exton, PA

mesothelioma
--------------------------------
solid tumors

Phase II
www.eisai.com
--------------------------------
Phase I
www.eisai.com

NC-6004
(nanoparticle cisplatin)

NanoCarrier
Tokyo, Japan

NSCLC

Phase I/II
www.nanocarrier.co.jp

necitumumab
(EGFR inhibitor)

Lilly
Indianapolis, IN

squamous NSCLC

Phase III
www.lilly.com

nivolumab
(PD-1 inhibitor)

Bristol-Myers Squibb
Princeton, NJ

NSCLC (1st-line), squamous NSCLC (2nd-line), non-squamous NSCLC (2nd-line)
(see also brain, colorectal, head/neck, hematological, kidney, liver, lymphoma, skin, solid tumors)
--------------------------------
squamous NSCLC (3rd-line)
--------------------------------
NSCLC, SCLC

Phase III
www.bms.com

--------------------------------
Phase II
www.bms.com
--------------------------------
Phase II
www.bms.com

nivolumab + Yervoy?
ipilimumab

Bristol-Myers Squibb
Princeton, NJ

NSCLC, SCLC
(see also brain, colorectal, head/neck, hematological, kidney, skin)

Phase I
www.bms.com

patritumab
(anti-HER3 antibody)

Daiichi Sankyo
Parsippany, NJ

NSCLC
(see also breast)

Phase II
www.dsi.com

PDT with Photofrin?
por­fimer sodium
ORPHAN DRUG

Pinnacle Biologics
Bannockburn, IL

epithelioid malignant pleural
mesothelioma
(see also liver)

Phase III
www.pinnaclebiologics.com

pelareorep

Oncolytics Biotech
Calgary, Canada

NSCLC, squamous cell carcinoma of the lung
(see also colorectal, head/neck, myeloma, ovarian, pancreatic, skin, solid tumors, other)

Phase II
www.oncolyticsbiotech.com

pictrelisib
(PI3K inhibitor)

Genentech
South San Francisco, CA

metastatic NSCLC
(see also breast)

Phase II
www.gene.com

PRAME immunotherapeutic
(recombinant antigen-speci­fic cancer immunotherapeutic)

GlaxoSmithKline
Research Triangle Park, NC

resectable NSCLC

Phase II
www.gsk.com

PT 107
(allogeneic B7.1/HLA-A1 transfected tumor cell vaccine)

Pique Therapeutics
Durham, NC

NSCLC

Phase II
www.piquetherapeutics.com

RG7446
(anti-PD-L1 mAb)

Genentech
South San Francisco, CA

NSCLC (2nd-line)
(see also bladder, kidney, skin)
--------------------------------
NSCLC (3rd-line)
--------------------------------
EGFR-positive NSCLC

Phase III
www.gene.com
--------------------------------
Phase II
www.gene.com
--------------------------------
Phase I
www.gene.com

rociletinib (CO-1686)
(EGFR inhibitor)

Clovis Oncology
Boulder, CO

EGFR-mutated NSCLC
(Breakthrough Therapy)

Phase II
www.clovisoncology.com

roniciclib
(CDK inhibitor)

Bayer HealthCare Pharmaceuticals
Whippany, NJ

SCLC

Phase II
www.bayerpharma.com

sapacitabine
ORPHAN DRUG

Cyclacel Pharmaceuticals
Berkeley Heights, NJ

NSCLC
(see also hematological, leukemia)

Phase II
www.cyclacel.com

SC16LD6.5
(antibody drug conjugate)

Stem CentRx
South San Francisco, CA

SCLC

Phase I/II
www.stemcentrx.com

seliciclib
(CDK inhibitor)

Cyclacel Pharmaceuticals
Berkeley Heights, NJ

NSCLC
(see also other)

Phase II
www.cyclacel.com

selumetinib
(MEK inhibitor)

Array BioPharma
Boulder, CO
AstraZeneca
Wilmington, DE

KRAS-positive NSCLC (2nd-line)
(see also other)
--------------------------------
KRAS-negative NSCLC (2nd-line)

Phase III
www.arraybiopharma.com
www.astrazeneca.com
--------------------------------
Phase III
www.arraybiopharma.com
www.astrazeneca.com

SPI-1620
(endothelin B receptor agonist)

Spectrum Pharmaceuticals
Henderson, NV

NSCLC
(see also liver)

Phase II
www.sppirx.com

Ta­finlar?
dabrafenib

GlaxoSmithKline
Research Triangle Park, NC

NSCLC
(Breakthrough Therapy)

Phase II
www.gsk.com

tarextumab
(anti-NOTCH 2/3)

OncoMed Pharmaceuticals
Redwood City, CA

SCLC
(see also pancreatic)

Phase I/II
www.oncomed.com

Tavocept?

BioNumerik Pharmaceuticals
San Antonio, TX

lung cancer

Phase III
www.bionumerik.com

tergenpumatucel-L

NewLink Genetics
Ames, IA

advanced or metastatic NSCLC

Phase II/III
www.newlinkgenetics.com

TG4010
(MVA-MUC1-IL2 cancer vaccine)

Transgene
Cambridge, MA

advanced NSCLC

Phase II/III
www.transgene.fr

TH-302
(hypoxia-activated prodrug)

EMD Serono
Rockland, MA
ThresholdPharmaceuticals
South San Francisco, CA

NSCLC
(see also hematological, pancreatic, skin, sarcoma, solid tumors)

Phase II
www.emdserono.com
www.thresholdpharm.com

topotecan liposomal

Spectrum Pharmaceuticals
Henderson, NV

lung cancer
(see also breast)

Phase I
www.sppirx.com

tremelimumab
(anti-CTLA-4 mAb)

MedImmune
Gaithersburg, MD

mesothelioma

Phase III
www.medimmune.com

tremelimumab
(anti-CTLA-4 mAb)/Iressa? ge­ tinib combination

AstraZeneca
Wilmington, DE
MedImmune
Gaithersburg, MD

NSCLC

Phase I
www.astrazeneca.com
www.medimmune.com

TSR-011
(ALK/TRK inhibitor)

TESARO
Waltham, MA

NSCLC

Phase I/II
www.tesarobio.com

TUSC2
(gene therapy)

Genprex
Austin, TX

NSCLC

Phase I/II
www.genprex.com

Vargatef?
nintedanib

Boehringer Ingelheim Pharmaceuticals
Ridge­ eld, CT

NSCLC
(see also ovarian)
--------------------------------
mesothelioma

Phase III
www.boehringer-ingelheim.com
--------------------------------
Phase II
www.boehringer-ingelheim.com

veliparib

AbbVie
North Chicago, IL

NSCLC
(see also brain, breast)

Phase III
www.abbvie.com

viagenpumatucel-L
(cancer immunotherapy)

Heat Biologics
Durham, NC

NSCLC

Phase II
www.heatbio.com

vinorelbine liposomal

Spectrum Pharmaceuticals
Henderson, NV

SCLC
(see also ovarian)

Phase I
www.sppirx.com

vintafolide
(folate-DAVLBH)

Endocyte
West Lafayette, IN

NSCLC
(see also solid tumors)

Phase II
www.endocyte.com

VS-6063
(FAK inhibitor)
ORPHAN DRUG

Verastem
Cambridge, MA

KRAS-mutant NSCLC, mesothelioma
(see also ovarian)

Phase II
www.verastem.com

Xalkori?
crizotinib
ORPHAN DRUG

P­fizer
New York, NY

ALK-positive NSCLC (1st-line)
(see also solid tumors)

Phase III
www.pfizer.com

Xgeva?
denosumab

Amgen
Thousand Oaks, CA

metastatic NSCLC (1st-line)
(see also breast)

Phase II
www.amgen.com

Yervoy?
ipilimumab

Bristol-Myers Squibb
Princeton, NJ

SCLC (1st-line), squamous NSCLC (1st-line)
(see also ovarian, prostate, skin, stomach)

Phase III
www.bms.com

Zykadia?
ceritinib

Novartis Pharmaceuticals
East Hanover, NJ

ALK-positive advanced NSCLC
(1st-line, treatment na?ve)

Phase II
www.novartis.com